Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
American Society of Clinical Oncology to hold a symposium » 04:55
01/25/20
01/25
04:55
01/25/20
04:55
AMZN

Amazon.com

$1,862.09 /

-22.76 (-1.21%)

, AGIO

Agios Pharmaceuticals

$53.04 /

-0.22 (-0.41%)

, AZN

AstraZeneca

$49.28 /

-0.93 (-1.85%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$64.18 /

-2.715 (-4.06%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ERYP

Erytech Pharma

$7.10 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$18.01 /

-1.57 (-8.02%)

, FGEN

FibroGen

$41.80 /

-2.35 (-5.32%)

, HSDEF

Harborside

$0.00 /

+ (+0.00%)

, INCY

Incyte

$76.66 /

-1.56 (-1.99%)

, LXRX

Lexicon

$3.37 /

-0.07 (-2.03%)

, MRK

Merck

$85.96 /

-2.56 (-2.89%)

, NTRA

Natera

$35.71 /

-1.08 (-2.94%)

, NVTA

Invitae

$18.35 /

-0.15 (-0.81%)

, PFE

Pfizer

$39.82 /

-0.89 (-2.19%)

, PGNX

Progenics

$4.65 /

-0.045 (-0.96%)

, SGEN

Seattle Genetics

$113.63 /

-1.69 (-1.47%)

, TROV

Trovagene

$1.69 /

-0.075 (-4.25%)

2020 Gastrointestinal…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Crohn's & Colitis Foundation to hold a conference » 04:55
01/25/20
01/25
04:55
01/25/20
04:55
ABBV

AbbVie

$83.53 /

-1.73 (-2.03%)

, ARNA

Arena Pharmaceuticals

$44.54 /

-1.27 (-2.77%)

, BMY

Bristol-Myers

$64.18 /

-2.715 (-4.06%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, GILD

Gilead

$63.12 /

-0.84 (-1.31%)

, LLY

Eli Lilly

$139.09 /

-2.14 (-1.52%)

, PFE

Pfizer

$39.82 /

-0.89 (-2.19%)

, TAK

Takeda Pharmaceutical

$19.84 /

-0.185 (-0.92%)

, UCBJF

UCB

$0.00 /

+ (+0.00%)

, UCBJY

UCB

$0.00 /

+ (+0.00%)

2020 Crohn's &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Yesterday
Options
Portola Pharmaceuticals call volume above normal and directionally bullish » 14:45
01/24/20
01/24
14:45
01/24/20
14:45
PTLA

Portola Pharmaceuticals

$13.43 /

-0.315 (-2.29%)

Bullish option flow…

Bullish option flow detected in Portola Pharmaceuticals with 1,855 calls trading, 1.1x expected, and implied vol increasing almost 2 points to 65.36%. Mar-20 12.5 calls and Mar-20 25 calls are the most active options, with total volume in those strikes near 1,600 contracts. The Put/Call Ratio is 0.07. Earnings are expected on February 28th.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Cowen says Blueprint a top pick after Ayvakit added to 4L GIST treatment » 13:21
01/24/20
01/24
13:21
01/24/20
13:21
BPMC

Blueprint Medicines

$66.67 /

-0.55 (-0.82%)

Cowen analyst Marc Frahm…

Cowen analyst Marc Frahm says the NCCN issued updated GIST treatment guidelines that include Ayvakit in PDGFR driven GIST and "surprisingly also" 4L GIST. Frahm tells investors in a research note that believes this will enable Ayvakit to begin entrenching itself in the broad GIST treatment landscape immediately and in advance of ripretinib's expected launch later in 2020. The analyst, who made no change to his Outperform rating, says Blueprint remains his top pick based upon Ayvakit's potential in indolent systemic mastocytosis.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23
    Jan
Recommendations
Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink » 12:48
01/24/20
01/24
12:48
01/24/20
12:48
BPMC

Blueprint Medicines

$65.60 /

-1.62 (-2.41%)

, DCPH

Deciphera

$66.22 /

+0.05 (+0.08%)

SVB Leerink analyst…

SVB Leerink analyst Andrew Berens tells investors in a research note that Ayvakit was added as a Category 2A recommendation for GIST for unresectable/metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation in the recently updated National Comprehensive Cancer Network Treatment Guidelines for Soft Tissue Sarcoma. Notably, he notes that Ayvakit was added as a recommendation in 4L GIST patients who have progressed following treatment with imatinib, sunitinib and regorafenib. The analyst says he views this as a strong endorsement from clinicians for Ayvakit in 4L GIST, and says this could put some pressure on the FDA to approve the drug and gives Blueprint Medicines (BPMC) a first-mover advantage in this setting vs. Deciphera's (DCPH) ripretinib in 4L GIST. The analyst made no change to his Outperform rating for Blueprint Medicines shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23
    Jan
Hot Stocks
Eli Lilly appoints Anat Hakim as general counsel » 06:32
01/24/20
01/24
06:32
01/24/20
06:32
LLY

Eli Lilly

$141.23 /

-0.36 (-0.25%)

, WCG

WellCare

$350.01 /

+4.22 (+1.22%)

Eli Lilly (LLY) announced…

Eli Lilly (LLY) announced that Anat Hakim will join the company on February 3 as senior vice-president and general counsel. Hakim succeeds Michael Harrington who will retire on January 31. Hakim most recently served as executive vice president, general counsel and secretary at WellCare Health Plans (WCG).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
American Society of Clinical Oncology to hold a symposium » 04:55
01/24/20
01/24
04:55
01/24/20
04:55
AMZN

Amazon.com

$1,884.85 /

-2.47 (-0.13%)

, AGIO

Agios Pharmaceuticals

$53.26 /

-0.54 (-1.00%)

, AZN

AstraZeneca

$50.21 /

-0.24 (-0.48%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$66.89 /

-0.53 (-0.79%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ERYP

Erytech Pharma

$7.10 /

-0.13 (-1.80%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$19.58 /

-0.14 (-0.71%)

, FGEN

FibroGen

$44.15 /

+0.37 (+0.85%)

, HSDEF

Harborside

$0.00 /

+ (+0.00%)

, INCY

Incyte

$78.22 /

-0.25 (-0.32%)

, LXRX

Lexicon

$3.44 /

-0.33 (-8.75%)

, MRK

Merck

$88.52 /

-1.13 (-1.26%)

, NTRA

Natera

$36.79 /

-0.37 (-1.00%)

, NVTA

Invitae

$18.50 /

-0.265 (-1.41%)

, PFE

Pfizer

$40.71 /

+0.52 (+1.29%)

, PGNX

Progenics

$4.70 /

+0.03 (+0.64%)

, SGEN

Seattle Genetics

$115.32 /

+3.61 (+3.23%)

, TROV

Trovagene

$1.77 /

+0.035 (+2.02%)

2020 Gastrointestinal…

2020 Gastrointestinal Cancers Symposium will be held in San Francisco on January 23-25.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Crohn's & Colitis Foundation to hold a conference » 04:55
01/24/20
01/24
04:55
01/24/20
04:55
ABBV

AbbVie

$85.26 /

-1.91 (-2.19%)

, ARNA

Arena Pharmaceuticals

$45.81 /

-0.06 (-0.13%)

, BMY

Bristol-Myers

$66.89 /

-0.53 (-0.79%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, GILD

Gilead

$63.96 /

+0.46 (+0.72%)

, LLY

Eli Lilly

$141.23 /

-0.36 (-0.25%)

, PFE

Pfizer

$40.71 /

+0.52 (+1.29%)

, TAK

Takeda Pharmaceutical

$20.02 /

+0.1 (+0.50%)

, UCBJF

UCB

$0.00 /

+ (+0.00%)

, UCBJY

UCB

$0.00 /

+ (+0.00%)

2020 Crohn's &…

2020 Crohn's & Colitis Congress will be held in Austin, Texas on January 23-25.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Hot Stocks
Acceleron Chief Business Officer John Quisel to step down » 16:16
01/23/20
01/23
16:16
01/23/20
16:16
XLRN

Acceleron

$52.75 /

-0.235 (-0.44%)

Acceleron Pharma…

Acceleron Pharma announced that John Quisel, Executive Vice President and Chief Business Officer, is leaving the company to become CEO of a venture-backed startup biotechnology company. Dr. Quisel's departure from Acceleron is effective as of February 24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Kura Oncology appoints Bridget Martell acting Chief Medical Officer » 16:13
01/23/20
01/23
16:13
01/23/20
16:13
KURA

Kura Oncology

$12.25 /

-0.4 (-3.16%)

Kura Oncology announced…

Kura Oncology announced that Antonio Gualberto, M.D., Ph.D., will step down as Head of Development and Chief Medical Officer to pursue other opportunities. Bridget Martell, M.A., M.D., currently VP of Clinical Development at Kura, has been named acting Chief Medical Officer while the company completes an executive search. Dr. Gualberto plans to serve in an advisory capacity during the transition, which will take effect on February 7.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.